A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Who May Qualify: - Have documented diagnosis of SCLE or CCLE that has been confirmed by biopsy with or without systemic LE manifestations. - Have a total CLASI-A score of ≥10 at Screening and Day 1. Participants with a CLASI-A score of ≥8 and \<10 are eligible if the score does not include alopecia and/or mucous membrane lesions. - Have active CLE despite an adequate trial of conventional therapies. - Are positive for at least one autoantibody at Screening. Who Should NOT Join This Trial: - Have known or suspected drug-induced CLE anti-phospholipid disease, or neuropsychiatric SLE. - Have rapidly progressive nephritis. - Have current inflammatory skin disease other than SCLE/CCLE that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments or confound the disease activity assessments. Note: Other protocol defined Inclusion/Exclusion criteria may apply Always talk to your doctor about whether this trial is right for you.